STAAR Surgical Company (STAA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by STAAR Surgical Company on June 9, 2026, reporting events that occurred on June 8, 2026. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments.
Material Changes
The Compensation Committee of the Board of Directors approved the following changes effective June 8, 2026, for Deborah Andrews, Interim Co-Chief Executive Officer and Chief Financial Officer:
- Base Salary: Increased from $512,000 to $575,000 annually.
- Target Annual Cash Bonus: Increased from 55% to 60% of base salary.
These adjustments were made following a review of competitive market data and in recognition of Ms. Andrews' contributions to the Company's strategic and operational objectives.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total annual compensation impact of the salary and bonus increase for the Interim Co-CEO/CFO.
- Confirm the duration of the interim leadership roles for Deborah Andrews and Warren Foust.
- Review the competitive market data cited by the Compensation Committee to justify the increase.
- Check for any related proxy statements or future filings regarding the permanent appointment of executive leadership.